4.6 Review

Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier

期刊

EXPERT OPINION ON DRUG DELIVERY
卷 17, 期 1, 页码 23-32

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/17425247.2020.1698544

关键词

BDNF; blood-brain barrier (BBB); enzymes; enzyme replacement therapy (ERT); GDNF; lysosomal storage diseases (LSDs); macromolecules; nanomedicine; nanoparticles; neurotrophic factor; nerve growth factor (NGF)

资金

  1. MAECI [MAE0066134]

向作者/读者索取更多资源

Introduction: Current therapies of neurodegenerative or neurometabolic diseases are, to a large extent, hampered by the inability of drugs to cross the blood-brain barrier (BBB). This very tight barrier severely restricts the entrance of molecules from the blood into the brain, especially macromolecular substances (i.e. neurotrophic factors, enzymes, proteins, as well as genetic materials). Due to their size, physicochemical properties, and instability, the delivery of these materials is particularly difficult. Areas covered: Recent research showed that biocompatible and biodegradable nanoparticles possessing tailored surface properties can enable a delivery of drugs and specifically of macromolecules across the blood-brain barrier by using carrier systems of the brain capillary endothelium (Trojan Horse strategy). In the present review, the state-of-art of nanoparticle-mediated drug delivery of different macromolecular substances into the brain following intravenous injection is summarized, and different nanomedicines that are used to enable the transport of neurotrophic factors and enzymes across the blood-brain barrier into the CNS are critically analyzed. Expert opinion: Brain delivery of macromolecules by an intravenous application using nanomedicines is now a growing area of interest which could be really translated into clinical application if dedicated effort will be given to industrial scale-up production.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据